{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-162578","form_type":"8-K","ticker":"CATX","cik":"0000728387","company_name":"Perspective Therapeutics, Inc.","filed_at":"2026-04-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.685213+00:00","generated_at":"2026-05-15T05:25:10.297457+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Perspective reports 43% ORR, clean safety for [212Pb]VMT-α-NET in Phase 1/2a at AACR 2026","bullets":["Objective response rate 43% (10/23) in Cohort 2 first half; 9 patients with deepening response since ESMO 2025.","Safety (n=64): no DLTs, no Grade 4/5 AEs, no treatment-related discontinuations, no renal complications.","18 of 25 patients (72%) progression-free in Cohorts 1 and 2 first half as of March 4, 2026 data cutoff.","Initial efficacy data from additional 23 Cohort 2 and first 8 Cohort 3 patients expected later 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-162578","json":"https://secwatch.observer/filing/0001193125-26-162578.json","markdown":"https://secwatch.observer/filing/0001193125-26-162578.md","text":"https://secwatch.observer/filing/0001193125-26-162578.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/728387/000119312526162578/0001193125-26-162578-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/728387/000119312526162578/catx-20260418.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T05:25:10.297457+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}